The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study
Open accessAbstract
OBJECTIVE: To study the safety and efficacy of a cholinesterase inhibitor, donepezil hydrochloride, for the treatment of dementia in Parkinson's disease (PD). METHODS: This was a randomised double blind, placebo controlled, crossover study in 22 subjects with PD and dementia. Participants were randomised to receive either donepezil followed by identical placebo, or placebo followed by donepezil. Donepezil was administered at 5-10 mg/day. Treatment periods were 10 weeks with a washout period of 6 weeks between the two periods. The primary outcome measure was the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAScog). RESULTS: Donepezil was well tolerated and most adverse events were mild. There was no worsening of PD symptoms as measured by the total or motor sections of the Unified Parkinson's Disease Rating Scale.There was a 1.9 point trend toward better scores on the ADAScog on treatment compared with placebo that was not statistically significant. The secondary cognitive measures showed a statistically significant 2 point benefit on the Mini Mental Status Examination and no change on the Mattis Dementia Rating Scale (MDRS). The Clinical Global Impression of Change (CGI) showed a significant 0.37 point improvement on donepezil. No improvement was observed on the MDRS or the Brief Psychiatric Rating Scale. Carryover between treatment periods was observed but was not statistically significant. CONCLUSIONS: Donepezil was well tolerated and did not worsen PD. There may be a modest benefit on aspects of cognitive function. The possible clinical benefit measured by CGI was reflected in only one of the cognitive scales used in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Van Den Eeden, S. K. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,747
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
A stagewise rejective multiple test procedure based on a modified Bonferroni test
HOMMEL, G. (1988) · Biometrika · doi:10.1093/biomet/75.2.383 · Cited by 1,367
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I., Quinn, N., Sethi, K. D., Shults, C., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,009
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 773
Cross-Over Trials in Clinical Research
(1994) · Technometrics · doi:10.1080/00401706.1994.10485798 · Cited by 763
Rogers, S. L., & Friedhoff, L. T. (1996) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106895 · Cited by 742
Cross‐over Trials In Clinical Research
Senn, S. (2002) · doi:10.1002/0470854596 · Cited by 653
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease
Hurtig, H. I., Trojanowski, J. Q., Galvin, J., Ewbank, D., Schmidt, M. L., Lee, V. M. Y., Clark, C. M., Glosser, G., Stern, M. B., Gollomp, S. M., et al. (2000) · Neurology · doi:10.1212/wnl.54.10.1916 · Cited by 601
Perry, E. K., Curtis, M., Dick, D. J., Candy, J. M., Atack, J. R., Bloxham, C. A., Blessed, G., Fairbairn, A., Tomlinson, B. E., & Perry, R. H. (1985) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.5.413 · Cited by 571
Report of the second dementia with Lewy body international workshop: Diagnosis and treatment
McKeith, I. G., Perry, E. K., & Perry, R. H. (1999) · Neurology · doi:10.1212/wnl.53.5.902 · Cited by 460
Pathological changes in the nucleus of meynert in Alzheimer's and Parkinson's diseases
Candy, J. M., Perry, R. H., Perry, E. K., Irving, D., Blessed, G., Fairbairn, A. F., & Tomlinson, B. E. (1983) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(83)90045-x · Cited by 459
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
Aarsland, D. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.708 · Cited by 341
Hobson, P., & Meara, J. (2004) · Movement Disorders · doi:10.1002/mds.20216 · Cited by 312
The association of incident dementia with mortality in PD
Levy, G., Tang, M.-X., Louis, E. D., Côté, L. J., Alfaro, B., Mejia, H., Stern, Y., & Marder, K. (2002) · Neurology · doi:10.1212/01.wnl.0000036610.36834.e0 · Cited by 297
Ruberg, M., Ploska, A., Javoy-Agid, F., & Agid, Y. (1982) · Brain Research · doi:10.1016/0006-8993(82)90615-1 · Cited by 263
Siderowf, A., McDermott, M., Kieburtz, K., Blindauer, K., Plumb, S., Shoulson, I., & the Parkinson Study Group (2002) · Movement Disorders · doi:10.1002/mds.10011 · Cited by 234
Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease
Leroi, I., Brandt, J., Reich, S. G., Lyketsos, C. G., Grill, S., Thompson, R., & Marsh, L. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.993 · Cited by 226
Combined effect of age and severity on the risk of dementia in Parkinson's disease
Levy, G., Schupf, N., Tang, M., Cote, L. J., Louis, E. D., Mejia, H., Stern, Y., & Marder, K. (2002) · Annals of Neurology · doi:10.1002/ana.10219 · Cited by 209
The nucleus basalis of Meynert in neurological disease: A quantitative morphological study
Rogers, J. D., Brogan, D., & Mirra, S. S. (1985) · Annals of Neurology · doi:10.1002/ana.410170210 · Cited by 200
Alzheimer's Disease Assessment Scale (ADAS).
Mohs, R. C., & Cohen, L. (1988) · PubMed · Cited by 199
Mortality From Parkinson Disease
Louis, E. D., Marder, K., Cote, L., Tang, M., & Mayeux, R. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550150024011 · Cited by 165
The Physiology and Pharmacology of Melatonin in Humans
Geoffriau, M., Brun, J., Chazot, G., & Claustrat, B. (1998) · Hormone Research in Paediatrics · doi:10.1159/000023160 · Cited by 164
Quetiapine improves psychotic symptoms and cognition in Parkinson's disease
Juncos, J. L., Roberts, V. J., Evatt, M. L., Jewart, R. D., Wood, C. D., Potter, L. S., Jou, H.-C., & Yeung, P. P. (2004) · Movement Disorders · doi:10.1002/mds.10620 · Cited by 126
Cholinesterase Inhibitor Therapies and Neuropsychiatric Manifestations of Alzheimer’s Disease
Wynn, Z. J., & Cummings, J. L. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000074281 · Cited by 118
Dementia with Lewy bodies and Parkinson's disease
McKeith, I. G., & Mosimann, U. P. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2003.12.005 · Cited by 109
The pharmacology of donepezil: a new treatment for Alzheimer’s disease
Wilkinson, D. G. (1999) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.1.121 · Cited by 97
Differential diagnosis of jaundice.
Rovner, B. W., & Folstein, M. F. (1987) · PubMed · Cited by 79
Paolo, A. M., Tröster, A. I., Glatt, S. L., Hubble, J. P., & Koller, W. C. (1995) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879500800308 · Cited by 72
The Relationship Between Donepezil and Behavioral Disturbances in Patients With Alzheimer's Disease
Cummings, J. L., Donohue, J. A., & Brooks, R. L. (2000) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200005000-00008 · Cited by 71
Richard, I. H., Justus, A. W., Greig, N. H., Marshall, F. J., & Kurlan, R. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200211000-00002 · Cited by 42
Putt, M., & Ravina, B. M. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(01)00207-0 · Cited by 24
Self-citationThe association of incident dementia with mortality in PD
Jellinger, K. (2003) · Neurology · doi:10.1212/wnl.61.3.424 · Cited by 19
Shinotoh, H., Namba, H., Yamaguchi, M., Fukushi, K., Nagatsuka, S., Iyo, M., Asahina, M., Hattori, T., Tanada, S., & Irie, T. (2001) · PubMed · Cited by 16
Dementia with Lewy bodies and Parkinson's disease
(2005) · CRC Press eBooks · doi:10.1201/b13239-84 · Cited by 7
COMT (catechol‐ O ‐methyltransferase)
Gogos, J. A. (2002) · Wiley eBooks · doi:10.1002/0471203076.emm0386 · Cited by 5
Cited by
Parkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Ray Chaudhuri, K., & Weintraub, D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,371
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
A review of Parkinson's disease
Davie, C. A. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn013 · Cited by 855
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Metadata
- Authors
- Ravina, B.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2005-07-01
- Volume
- 76
- Issue
- 7
- Pages
- 934-939
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2077633683
- Cited by
- 273
- References
- 38
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.